Claudin-5 is involved in breast cancer cell motility through the N-WASP and ROCK signalling pathways

Journal of Experimental & Clinical Cancer Research

Tracey A Martin¹  Wen G Jiang¹  Astrid Escudero-Esparza¹ 

[1] Metastasis and Angiogenesis Research Group, Institute of Cancer and Genetics, Cardiff University School of Medicine, Heath Park, Cardiff, CF14 4XN, UK

关键词: ROCK;    N-WASP;    MDA-MB-231;    Claudin-5;    Breast cancer;   

Others  :  826460
DOI  :  10.1186/1756-9966-31-43

 received in 2012-01-25, accepted in 2012-02-18,  发布年份 2012

【 摘 要 】

Background

Recent studies have shown dysregulation in TJ structure of several cancers including breast. Claudin-5 is a protein member of the TJ structure expressed in both endothelial and epithelial cells. This study examined the level of expression and distribution of Claudin-5 in human breast cancer tissues and the effect of knockdown and forced expression of Claudin-5 in the MDA-MB-231 breast cancer cell line.

Methods

Immunohistochemistry and quantitative-PCR were used to analyse patient tissue samples. The Claudin-5 gene was cloned and overexpressed or knocked down using ribozyme technology in human breast cancer cells. Changes in function were assessed using in vitro assays for invasion, growth, adhesion, wounding, motility, transepithelial resistance and electric cell-substrate impedance sensing. Changes in cell behaviour were achieved through the use of Hepatocyte Growth factor (HGF) which we have shown to affect TJ function and expression of TJ proteins. In addition, an in vivo model was used for tumour growth assays. Results data was analyzed using a Students two sample t-test and by Two-way Anova test when the data was found to be normalized and have equal variances. In all cases 95% confidence intervals were used.

Results

Patients whose tumours expressed high levels of Claudin-5 had shorter survival than those with low levels (p = 0.004). Investigating in vitro the effect of altering levels of expression of Claudin-5 in MDA-MB-231cells revealed that the insertion of Claudin-5 gene resulted in significantly more motile cells (p < 0.005). Low levels of Claudin-5 resulted in a decrease in adhesion to matrix (p < 0.001). Furthermore, a possible link between Claudin-5 and N-WASP, and Claudin-5 and ROCK was demonstrated when interactions between these proteins were seen in the cells. Moreover, followed by treatment of N-WASP inhibitor (Wiskostatin) and ROCK inhibitor (Y-27632) cell motility was assessed in response to the inhibitors. Results showed that the knockdown of Claudin-5 in MDA-MB-231 masked their response after treatment with N-WASP inhibitor; however treatment with ROCK inhibitor did not reveal any differences in motility in this cell line.

Conclusions

This study portrays a very new and interesting role for Claudin-5 in cell motility involving the N-WASP signalling cascade indicating a possible role for Claudin-5 in the metastasis of human breast cancer.

【 授权许可】

   
2012 Escudero-Esparza et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Crnic I, Christofori G: Novel technologies and recent advances in metastasis research. Int J Dev Biol 2002, 48(5–6):573-581.
• [2]Yang J, Mani SA, Weinberg RA: Exploring a new twist on tumor metastasis. Cancer Res 2006, 66(9):4549-4552.
• [3]Nishimura Y, Itoh K, Yoshioka K, Tokuda K, Himeno M: Overexpression of ROCK in human breast cancer cells: evidence that ROCK activity mediates intracellular membrane traffic of lysosomes. Pathol Oncol Res 2002, 9(2):83-95.
• [4]Martin TA, Das T, Mansel RE, Jiang WG: Synergistic regulation of endothelial tight junctions by antioxidant (Se) and polyunsaturated lipid (GLA) via Claudin-5 modulation. J Cell Biochem 2002, 98(5):1308-1319.
• [5]Paschoud S, Bongiovanni M, Pache JC, Citi S: Claudin-1 and Claudin-5 expression patterns differentiate lung squamous cell carcinomas from adenocarcinomas. Mod Pathol 2002, 20(9):947-954.
• [6]Turunen M, Talvensaari-Mattila A, Soini Y, Santala MZ: Claudin-5 overexpression correlates with aggressive behavior in serous ovarian adenocarcinoma. Anticancer Res 2002, 29(12):5185-5189.
• [7]Arshad F, Wang L, Sy C, Avraham S, Avraham HK: Blood-brain barrier integrity and breast cancer metastasis to the brain. Patholog Res Int 2010, 2011:920509.
• [8]Martin TA, Mason MD, Jiang WG: Tight junctions in cancer metastasis. Front Biosci 2011, 16:898-936.
• [9]Cereijido M, Contreras RG, Shoshani L, Flores-Benitez D, Larre I: Tight junction and polarity interaction in the transporting epithelial phenotype. Biochim Biophys Acta 2008, 1778(3):770-793.
• [10]Tsukita S, Furuse M: Pores in the wall: claudins constitute tight junction strands containing aqueous pores. J Cell Biol 2000, 149(1):13-16.
• [11]Ohkubo T, Ozawa M: J The transcription factor Snail downregulates the tight junction components independently of E-cadherin downregulation. Cell Sci 2002, 117(Pt 9):1675-1685.
• [12]Morita K, Furuse M, Fujimoto K, Tsukita S: Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc Natl Acad Sci U S A 1999, 96(2):511-516.
• [13]Furuse M, Sasaki H, Tsukita S: Manner of interaction of heterogeneous claudin species within and between tight junction strands. J Cell Biol 1999, 147(4):891-903.
• [14]Tsukita S: Isolation of cell-to-cell adherens junctions from rat liver. J Cell Biol 1989, 108(1):31-41.
• [15]Van Itallie CM, Anderson JM: Claudins and epithelial paracellular transport. Annu Rev Physiol 2006, 68:403-429.
• [16]Morita K, Sasaki H, Furuse M, Tsukita S: Endothelial claudin: Claudin-5/TMVCF constitutes tight junction strands in endothelial cells. J Cell Biol 1999, 147(1):185-194.
• [17]Rahner C, Mitic LL, Anderson JM: Heterogeneity in expression and subcellular localization of claudins 2, 3, 4, and 5 in the rat liver, pancreas, and gut. Gastroenterology 2009, 120(2):411-422.
• [18]Amasheh S, Schmidt T, Mahn M, et al.: Contribution of Claudin-5 to barrier properties in tight junctions of epithelial cells. Cell Tissue Res 2005, 321(1):89-96.
• [19]Wolburg H, Wolburg-Buchholz K, Kraus J, et al.: Localization of claudin-3 in tight junctions of the blood-brain barrier is selectively lost during experimental autoimmune encephalomyelitis and human glioblastoma multiforme. Acta Neuropathol 2003, 105(6):586-592.
• [20]Nitta T, Hata M, Gotoh S, et al.: Size-selective loosening of the blood-brain barrier in Claudin-5-deficient mice. J Cell Biol 2003, 161(3):653-660.
• [21]Martin TA, Watkins G, Mansel RE, Jiang WG: Hepatocyte growth factor disrupts tight junctions in human breast cancer cells. Cell Biol Int 2004, 28(5):361-371.
• [22]Martin TA, Watkins G, Mansel RE, Jiang WG: Loss of tight junction plaque molecules in breast cancer tissues is associated with a poor prognosis in patients with breast cancer. Eur J Cancer 2004, 40(18):2717-2725.
• [23]Jiang WG, Davies G, Martin TA, et al.: Targeting matrilysin and its impact on tumor growth in vivo: the potential implications in breast cancer therapy. Clin Cancer Res 2003, 11(16):6012-6019.
• [24]Jiang WG, Hiscox SE, Parr C, et al.: Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells. Clin Cancer Res 1999, 5(11):3695-3703.
• [25]Martin TA, Pereira G, Watkins G, Mansel RE, Jiang WG: N-WASP is a putative tumour suppressor in breast cancer cells, in vitro and in vivo, and is associated with clinical outcome in patients with breast cancer. Clin Exp Metastasis 2008, 25(2):97-108.
• [26]Martin TA, Harrison GM, Watkins G, Jiang WG: Claudin-16 reduces the aggressive behavior of human breast cancer cells. J Cell Biochem 2008, 105(1):41-52.
• [27]Jiang WG, Hiscox S, Hallett MB, Scott C, Horrobin DF, Puntis MC: Inhibition of hepatocyte growth factor-induced motility and in vitro invasion of human colon cancer cells by gamma-linolenic acid. Br J Cancer 1995, 71(4):744-752.
• [28]Hoover KB, Liao SY, Bryant PJ: Loss of the tight junction MAGUK ZO-1 in breast cancer: relationship to glandular differentiation and loss of heterozygosity. Am J Pathol 1999, 153(6):1767-1773.
• [29]Martin TA, Mansel RE, Jiang WG: Loss of occludin leads to the progression of human breast cancer. Int J Mol Med 2010, 26(5):723-734.
• [30]Ito T, Kojima T, Yamaguchi H, Kyuno D, Kimura Y, Imamura M, Takasawa A, Murata M, Tanaka S, Hirata K, Sawada N: Transcriptional regulation of claudin-18 via specific protein kinase C signaling pathways and modification of DNA methylation in human pancreatic cancer cells. J Cell Biochem 2011, 7:1761-1772.
• [31]Coutinho-Camillo CM, Lourenço SV, da Fonseca FP, Soares FA: Claudin expression is dysregulated in prostate adenocarcinomas but does not correlate with main clinicopathological parameters. Pathology 2011, 43(2):143-148.
• [32]Michl P, Barth C, Buchholz M, et al.: Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer. Cancer Res 2003, 63(19):6265-6271.
• [33]Felding-Habermann B, O’Toole TE, Smith JW, et al.: Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci U S A 2009, 98(4):1853-1858.
• [34]Insall RH, Jones GE: Moving matters: signals and mechanisms in directed cell migration. Nat Cell Biol 2006, B(8):776-779.
• [35]Jiang WG, Martin TA, Parr C, Davies G, Matsumoto K, Nakamura T: Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol 2005, 53(1):35-69.
• [36]Lu Z, Ding L, Hong H, Hoggard J, Lu Q, Chen YH: Claudin-7 inhibits human lung cancer cell migration and invasion through ERK/MAPK signalling pathway. Exp Cell Res 2011, 1;317(13):1935-1946.
• [37]Dovas A, Cox D: Regulation of WASp by phosphorylation: Activation or other functions? Commun Integr Biol 2010, 3(2):101-105.
• [38]Lane J, Martin TA, Watkins G, Mansel RE, Jiang WG: The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer. Int J Oncol 2008, 33(3):585-593.
• [39]Guerriero CJ, Weisz OA: N-WASP inhibitor wiskostatin nonselectively perturbs membrane transport by decreasing cellular ATP levels. Am J Physiol Cell Physiol 2007, 292(4):C1562-C1566.
• [40]Grise F, Bidaud A, Moreau V: Rho GTPases in hepatocellular carcinoma. Biochim Biophys Acta 2009, 1795(2):137-151.
• [41]Ivanov AI, Hunt D, Utech M, Nusrat A, Parkos CA: Differential roles for actin polymerization and a myosin II motor in assembly of the epithelial apical junctional complex. Mol Biol Cell 2005, 16(6):2636-2650.
• [42]Seo KW, Kwon YK, Kim BH, et al.: Correlation between Claudins Expression and Prognostic Factors in Prostate Cancer. Korean J Urol 2010, 51(4):239-244.
• [43]Sakaguchi T, Suzuki S, Higashi H, et al.: Expression of tight junction protein Claudin-5 in tumor vessels and sinusoidal endothelium in patients with hepatocellular carcinoma. J Surg Res 2008, 47(1):123-131.
• [44]Prat A, Parker JS, Karingova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM: Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Can Res 2010, 12:R68. BioMed Central Full Text